ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 1.5B 3B 4.5B Q1 '21: 570.9M Q2 '21: 687.5M Q3 '21: 749.3M Q4 '21: 844.3M Q1 '22: 880M Q2 '22: 884.2M Q3 '22: 960.9M Q4 '22: 1B Q1 '23: 1.1B Q2 '23: 1.2B Q3 '23: 1.7B Q4 '23: 1.8B Q1 '24: 2B Q2 '24: 2.3B Q3 '24: 2.1B Q4 '24: 2.2B Q1 '25: 2.3B Q2 '25: 2.5B Q3 '25: 3.2B Q4 '25: 3.7B Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-900M -600M -300M 0 300M 600M 900M Q1 '21: -804.5M Q2 '21: -751.8M Q3 '21: -708.3M Q4 '21: -708.7M Q1 '22: -669.1M Q2 '22: -714.7M Q3 '22: -791M Q4 '22: -785.1M Q1 '23: -788.1M Q2 '23: -826.3M Q3 '23: -354.4M Q4 '23: -282.2M Q1 '24: -175.8M Q2 '24: 102.6M Q3 '24: -188.1M Q4 '24: -176.9M Q1 '25: -115.4M Q2 '25: -180.2M Q3 '25: 264.7M Q4 '25: 501.6M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Net Income TTM

-1.5B -1B -500M 0 500M 1B 1.5B Q3 '21: -837.9M Q4 '21: -852.8M Q1 '22: -892.9M Q2 '22: -980.7M Q3 '22: -1.2B Q4 '22: -1.1B Q1 '23: -1.1B Q2 '23: -1.1B Q3 '23: -509.9M Q4 '23: -440.2M Q1 '24: -332.1M Q2 '24: -72.9M Q3 '24: -332.3M Q4 '24: -278.2M Q1 '25: -230.5M Q2 '25: -285.8M Q3 '25: 76.8M Q4 '25: 272.1M Q1 '26: 496.4M Q2 '26: 733.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 250M 500M 750M Q1 '21: 83.9M Q2 '21: 95.9M Q3 '21: 103.2M Q4 '21: 115M Q1 '22: 115.4M Q2 '22: 119.2M Q3 '22: 127.6M Q4 '22: 140.2M Q1 '23: 158.1M Q2 '23: 199.4M Q3 '23: 242.4M Q4 '23: 268.2M Q1 '24: 281.4M Q2 '24: 273.3M Q3 '24: 275.8M Q4 '24: 306.5M Q1 '25: 322.1M Q2 '25: 396.8M Q3 '25: 512.1M Q4 '25: 677.2M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating Cash Flow TTM

-750M -500M -250M 0 250M 500M 750M Q1 '21: -604.5M Q2 '21: -591M Q3 '21: -614.7M Q4 '21: -641.7M Q1 '22: -577.2M Q2 '22: -578.2M Q3 '22: -559.4M Q4 '22: -541.3M Q1 '23: -536.6M Q2 '23: -472.7M Q3 '23: 2M Q4 '23: 104.2M Q1 '24: 189.1M Q2 '24: 372.3M Q3 '24: 56.6M Q4 '24: -8.3M Q1 '25: -45.1M Q2 '25: -41.5M Q3 '25: 265.9M Q4 '25: 524.1M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Free Cash Flow TTM

-750M -500M -250M 0 250M 500M 750M Q1 '21: -672.4M Q2 '21: -653.5M Q3 '21: -690.9M Q4 '21: -718.1M Q1 '22: -654.3M Q2 '22: -660.1M Q3 '22: -631.7M Q4 '22: -613.3M Q1 '23: -604.6M Q2 '23: -540.7M Q3 '23: -66.6M Q4 '23: 41.9M Q1 '24: 127.8M Q2 '24: 318.9M Q3 '24: 16.1M Q4 '24: -42.6M Q1 '25: -75.4M Q2 '25: -78M Q3 '25: 221.4M Q4 '25: 465.4M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q2 '20: 114.9M Q3 '20: 116M Q1 '21: 117.1M Q2 '21: 117.8M Q3 '21: 119.1M Q1 '22: 120.4M Q2 '22: 120.9M Q3 '22: 122.2M Q1 '23: 124.1M Q2 '23: 124.7M Q3 '23: 131.3M Q1 '24: 126.1M Q2 '24: 126.7M Q3 '24: 128.6M Q1 '25: 129.7M Q2 '25: 130.6M Q3 '25: 137.3M Q2 '26: 138.3M Q1 '21 Q1 '22 Q1 '23 Q1 '24 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q1 '20: -8.03 Q2 '20: -7.57 Q3 '20: -7.83 Q4 '20: -7.45 Q1 '21: -7.54 Q2 '21: -7.59 Q3 '21: -7.13 Q4 '21: -7.20 Q1 '22: -7.49 Q2 '22: -8.17 Q3 '22: -9.77 Q4 '22: -9.29 Q1 '23: -8.69 Q2 '23: -8.61 Q3 '23: -4.14 Q4 '23: -3.55 Q1 '24: -2.67 Q2 '24: -0.59 Q3 '24: -2.61 Q4 '24: -2.17 Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.